Difference between revisions of "Xu X, et al, (2020), cited as Ref 66 in DOI:10.1007/s11886-020-01292-3 (Q10575)"
Jump to navigation
Jump to search
(Created claim: Fifth Author string (P153): Wang D, #quickstatements; #temporary_batch_1592503455634) |
(Created claim: Sixth Author string (P154): Fu B, #quickstatements; #temporary_batch_1592503575618) |
||
| Property / Sixth Author string | |||
| + | Fu B | ||
| Property / Sixth Author string: Fu B / rank | |||
| + | Normal rank | ||
Revision as of 18:07, 18 June 2020
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Xu X, et al, (2020), cited as Ref 66 in DOI:10.1007/s11886-020-01292-3
|
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
|
Statements
Q10356 (Deleted Item)
0 references
Effective treatment of severe COVID-19 patients with Tocilizumab (English)
0 references
Xu X
0 references
Han M
0 references
Li T
0 references
Sun W
0 references
Wang D
0 references
Fu B
0 references
